NASDAQ:MSLI

(MSLI) (MSLI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.30
$1.30
50-Day Range
N/A
52-Week Range
$0.70
$1.33
Volume
N/A
Average Volume
56,140 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MSLI stock logo

About (MSLI) Stock (NASDAQ:MSLI)

Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

MSLI Stock News Headlines

The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
See More Headlines
Receive MSLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (MSLI) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2015
Today
4/22/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:MSLI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Michael S. Cloutier
    Independent Chairman of the Board

  • Bio & Compensation - 
  • Barry Fishman
    Chief Executive Officer, Director

  • Bio & Compensation - 
  • Michael Scott Bumby
    Chief Financial Officer
  • Robert McLay
    Vice President - Sales and Marketing

  • Bio & Compensation - 
  • Frank Rotmann
    Vice President and Head of European Operations

  • Bio & Compensation - 
  • Robert Bloch M.D.
    Director

  • Bio & Compensation - 
  • Theresa Sheila Firestone
    Independent Director

  • Bio & Compensation - 
  • David D. Guebert CPA
    Independent Director

  • Bio & Compensation - 
  • Robert S. Pollock
    Independent Director

  • Bio & Compensation - 
  • Timothy G. Sorensen
    Independent Director

  • Bio & Compensation - 

MSLI Stock Analysis - Frequently Asked Questions

How were (MSLI)'s earnings last quarter?

(MSLI) (NASDAQ:MSLI) issued its quarterly earnings results on Monday, August, 10th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.03. The business earned $7.73 million during the quarter, compared to the consensus estimate of $17.19 million.

What other stocks do shareholders of (MSLI) own?
This page (NASDAQ:MSLI) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners